OCT 2 0 2004

PART B - FEE(S) TRANSMITTAL

Complete

send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 (703) 746-4000

or Fax

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block I for any change of aidress)

021121

7590

07/27/2004

OPPEDAHL AND LARSON LLP POBOX 5068 DILLON, CO 80435-5068

10/21/2004 BSAYASI2 00000080 09780060

01 FC:2501

685.00 OP

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUB FEE address above, or being facsimile transmitted to the USPTO (703) 746-4000, on the date indicated below.

Lori South (Signature) (Dat October 28 2004

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 09/780,066 02/09/2001 C. Neil Kitson TDIG.P-001 9997

TITLE OF INVENTION: SKIN TREATMENT COMPOSITION AND METHODS OF USE

APPLN. TYPE	SMALL ENTITY	ISSUE FEE		PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE]	
попрrovisional	YES	.\$66 5 .	\$1685 so		\$665	10/27/2004		•
EXAMINER		ART UNIT	٠	CLASS-SUBCLASS				
LAMM, MARINA		1616		424-401000				
1. Change of correspondence address or indication of "Fee Address" (3 CFR 1.363).		, ,	(1) the names of up to 3 registered patent attorneys 1 Oppedan 1 & Larson					- LI
☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.			or agents OR, alternatively, (2) the name of a single firm (having as a member a 2					
☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.			registered attorney or agent) and the names of un to					
ASSIGNEE NAME AND	RESIDENCE DATA TO B	R PRINTED ON TH	•	•		•		- .
				pear on the patent. If an assign for filing an assignment.	ee is identified helov	v. the docum	ent has been filed for	r
recordation as set forth in	n 37 CFR 3.11. Completion of	of this form is NOT a	ı substitute	for filing an assignment.	•	,		•
(A) NAME OF ASSIGN	EE .	(B) I	RESIDENC	CE: (CITY and STATE OR COL	INTRY)			
Please check the appropriate 4a. The following fcc(s) are	e assignce category or categor		ed on the p		orporation or other pr	ivate group e	entity 🚨 governmen	t -
M issue Fee			A check in the amount of the fee(s) is enclosed.					
D Publication Fee (No st	Publication Fee (No small entity discount permitted)		XXPayment by credit card. Form PTO-2038 is attached.					
☐ Advance Order - # of	Copies	X	The Dire	ctor is hereby authorized by chount Number 15-0610	arge the required fee	e(s), or credit extra copy o	t any overpayment, to	,
. Change in Entity Status	(from status indicated above))					· · · · · · · · · · · · · · · · · · ·	•
a. Applicant claims SM	AALL ENTITY status. See 37	CFR 1.27.	b. Applica	nt is not claiming SMALL ENT	ITY status. Sec. e.g.,	37 CFR 1.27	7(ģ)(2).	
he Director of the USPTO	is requested to apply the Issu			y) or to re-apply any previously				•
NOTE: The Issue Fee and P nterest as shown by the reco	ublication Fee (if required) words of the United States Pate	ill not be accepted fi nt and Trademark O	rom anyone ffice,	e other than the applicant; a regi	tered attorney or age	nt; or the ass	denntied above. ignee or other party in	ı
Authorized Signature)	· · · · · · · · · · · · · · · · · · ·	(Date)						, .
Marina	Las~	0.0	ctobe	r 26, 2004		•		
nis collection of information application. Confidential	on is required by 37 CFR 1.31 ty is governed by 35 U.S.C.	1. The information i	s required	to obtain or retain a benefit by the	e public which is to	file (and by the	ne USPTO to process)	,

submitting the completed application form to the USPTO. Time will vary left depending upon the individual case. Any comments on the amount of time you require to complete, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMIT THIS FORM WITH FEE(S)

PTOL-85 (Rev. 07/04) Approved for use through 04/30/2007.

OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

BEST AVAILABLE COPY

REQUEST FOR EXPEDITED ISSUANCE OF A CORRECTED PATENT

Pursuant to 37 CFR § 1.322(b) and MPEP § 1480.01, the undersigned requests a corrected patent.

Attached for convenient reference please find a copy of Form PTOL-85 received by USPTO on February 24, 2010. The Form PTOL-85 clearly shows the Attorney, Agent or firm to be:

Oppedahl & Larson LLP

Through the fault of the Patent and Trademark Office, the patent was issued with this on the front page:

(74) Attorney, Agent, or Firm-Oppendahl & Larson LLP

It will be appreciated that the prominence of the mistake (on the front page of the patent) is such that a certificate of correction would not be appropriate. It is thus requested that the Director issue a corrected patent in lieu thereof as a more appropriate form for certificate of correction, without expense to the patentee thereof. 37 CFR § 1.322(b).

Respectfully submitted,

/s/

Carl Oppedahl PTO Reg. No. 32746



(12) United States Patent Kitson et al.

(45) Date of Patent:

US 6,824,785 B1

(10) Patent No.:

Nov. 30, 2004

(54) SKIN TREATMENT COMPOSITION AND METHODS OF USE

(76) Inventors: C. Neil Kitson, 3414 W. King Edward

Ave., Vancouver, BC (CA), V6S 1M3; Jenifer L. Thewalt, 3670 Trinity St., Vancouver, B.C. (CA), V5A 1S6

Subject to any disclaimer, the term of this (*) Notice:

patent is extended or adjusted under 35 U.S.C. 154(b) by 318 days.

(21) Appl. No.: 09/780,060

(22) Filed: Feb. 9, 2001

Related U.S. Application Data

(60) Provisional application No. 60/181,374, filed on Feb. 9,

(51) **Int. Cl.**⁷ **A61K 7/00**; A61K 9/00; A61K 9/127

(52) U.S. Cl. 424/401; 424/400; 424/450; 514/937; 514/944

424/450; 514/937, 944

(56)References Cited

U.S. PATENT DOCUMENTS

7/1997 Elias et al. 5,643,899 A 5,720,963 A 2/1998 Smith

5,916,578 A * 6/1999 Kawada et al. 424/401

FOREIGN PATENT DOCUMENTS

wo WO-90/01323 A1 * 2/1990

OTHER PUBLICATIONS

"Concise Encyclopedia Chemistry", p. 599, 1994.*

Abraham, et al.; "Investigation of Membrane Structure and Dynamics by Deuterium NMR: Application to the Stratum Corneum" in Mechanisms of Transdermal Drug Delivery; Potts and Guy, eds.; 1997; pp163-198.

Wertz, et al; "Covalently Bound Lipids of Human Stratum Corneum"; J. Invest Dermatol 92:109-111, 1989;

Imokawa, et al.; Importance of intercellular lipids in waterretention properties of the stratum corneum: induction and recovery study of surfactant dry skin; Arch Dermatol Res (1989) 281:45-51.

Abraham, et al.; "Fusion Patterns of Liposomes Formed from Stratum Corneum Lipids"; J. Învest Dermatol 90:259-262; 1988.

Pilgram, et al.; "Electron Diffraction Provides New Information on Human Stratum Corneum Lipid Organization Studied in Relation to Depth and Temperature" J Invest Dermatol 113:403-409, 1999.

Kitson, et al.; "A Model Membrane Approach to the Epidermal Permeability Barrier"; American Chemical Society, 1994; pp 6707-6715.

Imokawa, et al.; "Selective Recovery of Deranged Water-Holding Properties by Stratum Corneum Lipids"; The Society for Investigative Dermatology, Inc. 1986; pp758–761. Wertz, et al.; "Essential Fatty Acids and Epidermal Integrity", Arch Dermatol-vol. 123, Oct. 1987; pp1381-1384. Bouwstra, et al.; "A Model Membrane Approach to the Epidermal Permeability Barrier: An X-ray Diffraction Study"; Biochemistry 1997; 7717–7725.

Imokawa; "Stratum Corneum Lipids Serve as a Bound-Water Modulator"; The Society for Investigative Dermatology, Inc. 1991; pp 845-851.

Man, et al; Exogenous Lipids Influence Permeability Barrier Recovery in Acetone-Treated Murine Skin; Arch Dermatol-vol. 129, Jun. 1993, pp 728-738.

Thewalt, et al., Models of Stratum Corneum Intercellular Membranes: The Sphingolipid Headgroup is a Determinant of Phase Behavior in Mixed Lipid Dispersions; Biochemical and Biophysical Research Communications, vol. 188, No. 3, 1992, pp 1247-1252.

Proksch, et al.; "Barrier Function Regulates Epidermal DNA Synthesis", The Journal of Clinical Investigation, Inc., vol. 87, May 1991, 1668-1673.

Schurer, et al., "The Biochemistry and Function af Stratum Corneum Lipids"; Advances in Lipid Research, vol. 24, pp 27–56; 1991.

Elias, et al.; "Structural and Lipid Biochemical Correlates of the Epidermal Permeability Barrier"; Advances in Lipid Research, vol. 24, pp. 1-26, 1991.

Abraham, et al.; "Interaction between corneocytes and stratum corneum lipid liposomes in vitro"; Elsevier Science Publishers B.V. (Biomedical Division) 1990, pp 119–125. Abraham, et al.; "Effect of epidermal acylglucosylceramides and acylceramides on the morphology of liposomes prepared from stratum corneum lipids"; Biochimica et Biophysica Acta 939 (1988) 403–408.

Ansari, et al.; "Fatty Acid Composition of the Living Layer and Stratum Corneum Lipids of Human Sole Skin Epidermis"; Lipids, vol. 5, No. 10, pp 838-845, 1970.

Wertz, et al.; "Hydroxyacid Derivatives in Human Epidermis"; Lipids. vol. 23, No. 5 (1988).

Cullis, et al.; "The Bilayer Stabilizing Role of Sphingomyelin in the Presence of Cholesterol"; Biochimica et Biophysica Acta, 597 (1980) 533-542.

Monash, et al.; "Location and Re-Formation of the Epithelial Barrier to Water Vapor"; A.M.A. Archives of Dermatology; vol. 73, Dec. 1958.

* cited by examiner

Primary Examiner—Gary Kunz Assistant Examiner-Marina Lamm

(74) Attorney, Agent, or Firm-Oppendahl & Larson LLP

ABSTRACT

A composition which when topically applied to the skin of a mammal reduces trans-epidermal water-loss and provides an improved epidermal barrier contains an aqueous dispersion of at least two lipids, preferably at least three lipids, in a non-crystalline phase lamellar array, preferably bilayer membranes in the form of liposomes. These lipids adopt a crystalline lamellar phase upon application to mammalian skin which resist washing with mild detergents and water. The composition can be formulated as a pharmaceutical preparation, and can be used in a method of recovering or otherwise improving a mammalian skin permeability barrier by administering the composition to the skin or hair and allowing the composition to dry. The dried composition adopts a crystalline lamellar phase after said administering to the skin. The composition thus provides a permeability barrier in cases where the natural barrier has been depleted, damaged or requires improvement. This barrier resists removal by detergent, solvent, or mechanical means over an extended period of time.

6 Claims, 5 Drawing Sheets